Steven D. Averbuch

Biography

 Dr. Averbuch is the Head, Precision Medicine within the Translational Medicine Division of R&D at Bristol-Myers Squibb.  In this role, Steve leads integrated biomarker and pharmacodiagnostic activities across the BMS R&D portfolio. Dr. Averbuch joined Bristol-Myers Squibb in 2006 and he has led the Pharmacodiagnostics Center of Excellence since 2008.  Other previous roles included: Leading the strategy, business development agreements and execution of external clinical collaborations for the company’s immuno-oncology pipeline; Executive sponsor and oversight for translational research activities for all late development and marketed oncology compounds;  Leader of corporate-wide strategic initiatives for Translational and Targeted Medicine; Co-leader of the Oncology early strategy team and that included responsibility for the execution of Phase 2 Oncology programs. Dr. Averbuch has made significant contributions to business development and he has participated in multiple successful licensing and acquisition deals. Dr. Averbuch previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland. Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and he is a co-author on one patent. He is currently on the Personalized Medicine Coalition Board of Directors, the Steering Committee of the National Biomarker Development Alliance, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation, and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations. Dr. Averbuch is the 2014 recipient of the University of Illinois College of Medicine Distinguished Alumnus Award.

Research Interest

 Pharmaceutical